Condition: Patients With PH1 Treated With Lumasiran in France · Sponsor: Hospices Civils de Lyon
Primary hyperoxaluria type 1 (PH1) is a rare genetic disease caused by mutation in the AGXT gene encoding the hepatic peroxisomal enzyme AGT. Reduced AGT activity results in increased glyoxylate and oxalate production, causing the formation of kidney stones, nephrocalcinosis and renal failure. Clinical trials of Lumasiran have provided information on the efficacy and safety of Lumasiran in the treatment of primary hyperoxaluria type 1. However, they do not provide data on long-term efficacy, safety and patient management. As part of the post-marketing follow-up of Lumasiran, in agreement with the authorities, this study proposes a retrospective and prospective follow-up over 5 years of pediatrics and adults patients treated in France with a standardized clinical, biological and radiological follow-up. The main objective is to monitor the evolution of PH1 parameters and particularly oxaluria before and after treatment.
This description comes directly from the study's public registry record.
Mélissa CLOAREC, Clinical Research Associate · 04 27 85 51 54 · melissa.cloarec@chu-lyon.fr
Sacha FLAMMIER, Project Manager · 04 72 68 13 49 · sacha.flammier@chu-lyon.fr
Always discuss trial participation with your own doctor first.
| CHU de Besançon | Besançon, France | Recruiting |
| Centre de Référence des Maladies Rénales Rares - Hospices Civils de Lyon - Service de Néphrologie et Rhumatologie Pédiatriques - Hôpital Femme Mère Enfant | Bron, France | Recruiting |
| Hopital Edouard Herriot | Lyon, France | Recruiting |
| AP-HM - Timone Enfants | Marseille, France | Recruiting |
| Hôpital Européen G. Pompidou | Paris, France | Recruiting |
| CHU Paris - Hôpital Necker-Enfants Malades | Paris, France | Recruiting |
| Hôpital Necker, APHP Paris, Service de néphrologie-dialyse, 149 rue de Sèvres | Paris, Île-de-France Region, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06225882